RNAM

About Avidity Biosciences Inc

Avidity Biosciences, Inc. is at the forefront of developing a novel class of oligonucleotide-based therapies, known as Antibody Oligonucleotide Conjugates (AOCs). Utilizing its proprietary AOC platform, the company engineers treatments that strategically merge the targeted delivery capabilities of monoclonal antibodies with the precise action of oligonucleotide-based therapeutics. This innovative method aims to reach cell and tissue types previously inaccessible to treatment, thereby more effectively addressing the fundamental genetic causes of various diseases. The company was established on November 13, 2012, by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick, and its main office is located in San Diego, California.

CEO: Sarah Boyce
IPO Date: Jun 12, 2020

Market Data

Open: $72.86
High: $72.86
Low: $72.86
Volume: 1
Avg Volume: 2.7M
52W High: $73.06
52W Low: $21.51

Valuation

Market Cap: $11B
Enterprise Value: $11B
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-664M
Revenue: $19M
Net Income: $-685M
Cash: $383M
Debt: $95M

Events

EarningsFeb 23

EPS est. -1.29733 · actual -1.59